BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

215 related articles for article (PubMed ID: 34007022)

  • 1. USP22 promotes HER2-driven mammary carcinoma aggressiveness by suppressing the unfolded protein response.
    Prokakis E; Dyas A; Grün R; Fritzsche S; Bedi U; Kazerouni ZB; Kosinsky RL; Johnsen SA; Wegwitz F
    Oncogene; 2021 Jun; 40(23):4004-4018. PubMed ID: 34007022
    [TBL] [Abstract][Full Text] [Related]  

  • 2. USP22 overexpression fails to augment tumor formation in MMTV-ERBB2 mice but loss of function impacts MMTV promoter activity.
    Kuang X; Salinger A; Benavides F; Muller WJ; Dent SYR; Koutelou E
    PLoS One; 2024; 19(1):e0290837. PubMed ID: 38236941
    [TBL] [Abstract][Full Text] [Related]  

  • 3. USP22 supports the aggressive behavior of basal-like breast cancer by stimulating cellular respiration.
    Prokakis E; Bamahmoud H; Jansari S; Fritsche L; Dietz A; Boshnakovska A; Rehling P; Johnsen SA; Gallwas J; Wegwitz F
    Cell Commun Signal; 2024 Feb; 22(1):120. PubMed ID: 38347585
    [TBL] [Abstract][Full Text] [Related]  

  • 4. USP22-dependent HSP90AB1 expression promotes resistance to HSP90 inhibition in mammary and colorectal cancer.
    Kosinsky RL; Helms M; Zerche M; Wohn L; Dyas A; Prokakis E; Kazerouni ZB; Bedi U; Wegwitz F; Johnsen SA
    Cell Death Dis; 2019 Dec; 10(12):911. PubMed ID: 31801945
    [TBL] [Abstract][Full Text] [Related]  

  • 5. USP22 exerts tumor-suppressive functions in colorectal cancer by decreasing mTOR activity.
    Kosinsky RL; Zerche M; Saul D; Wang X; Wohn L; Wegwitz F; Begus-Nahrmann Y; Johnsen SA
    Cell Death Differ; 2020 Apr; 27(4):1328-1340. PubMed ID: 31527800
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Absence of integrin α3β1 promotes the progression of HER2-driven breast cancer in vivo.
    Ramovs V; Secades P; Song JY; Thijssen B; Kreft M; Sonnenberg A
    Breast Cancer Res; 2019 May; 21(1):63. PubMed ID: 31101121
    [TBL] [Abstract][Full Text] [Related]  

  • 7. USP22 positively modulates ERα action via its deubiquitinase activity in breast cancer.
    Wang S; Zhong X; Wang C; Luo H; Lin L; Sun H; Sun G; Zeng K; Zou R; Liu W; Sun N; Song H; Liu W; Zhang Q; Liao Z; Teng X; Zhou T; Sun X; Zhao Y
    Cell Death Differ; 2020 Nov; 27(11):3131-3145. PubMed ID: 32494025
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ubiquitin-specific protease 22 is critical to in vivo angiogenesis, growth and metastasis of non-small cell lung cancer.
    Zhang K; Yang L; Wang J; Sun T; Guo Y; Nelson R; Tong TR; Pangeni R; Salgia R; Raz DJ
    Cell Commun Signal; 2019 Dec; 17(1):167. PubMed ID: 31842906
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Deubiquitinating enzyme USP22 positively regulates c-Myc stability and tumorigenic activity in mammalian and breast cancer cells.
    Kim D; Hong A; Park HI; Shin WH; Yoo L; Jeon SJ; Chung KC
    J Cell Physiol; 2017 Dec; 232(12):3664-3676. PubMed ID: 28160502
    [TBL] [Abstract][Full Text] [Related]  

  • 10. USP22 Functions as an Oncogenic Driver in Prostate Cancer by Regulating Cell Proliferation and DNA Repair.
    McCann JJ; Vasilevskaya IA; Poudel Neupane N; Shafi AA; McNair C; Dylgjeri E; Mandigo AC; Schiewer MJ; Schrecengost RS; Gallagher P; Stanek TJ; McMahon SB; Berman-Booty LD; Ostrander WF; Knudsen KE
    Cancer Res; 2020 Feb; 80(3):430-443. PubMed ID: 31740444
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Induction of EnR stress by Melatonin enhances the cytotoxic effect of Lapatinib in HER2-positive breast cancer.
    Sang X; Li L; Rui C; Liu Y; Liu Z; Tao Z; Cheng H; Liu P
    Cancer Lett; 2021 Oct; 518():82-93. PubMed ID: 34153400
    [TBL] [Abstract][Full Text] [Related]  

  • 12. USP22 promotes hypoxia-induced hepatocellular carcinoma stemness by a HIF1α/USP22 positive feedback loop upon TP53 inactivation.
    Ling S; Shan Q; Zhan Q; Ye Q; Liu P; Xu S; He X; Ma J; Xiang J; Jiang G; Wen X; Feng Z; Wu Y; Feng T; Xu L; Chen K; Zhang X; Wei R; Zhang C; Cen B; Xie H; Song P; Liu J; Zheng S; Xu X
    Gut; 2020 Jul; 69(7):1322-1334. PubMed ID: 31776228
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeting Gi/o protein-coupled receptor signaling blocks HER2-induced breast cancer development and enhances HER2-targeted therapy.
    Lyu C; Ye Y; Lensing MM; Wagner KU; Weigel RJ; Chen S
    JCI Insight; 2021 Sep; 6(18):. PubMed ID: 34343132
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mcl-1 confers protection of Her2-positive breast cancer cells to hypoxia: therapeutic implications.
    Bashari MH; Fan F; Vallet S; Sattler M; Arn M; Luckner-Minden C; Schulze-Bergkamen H; Zörnig I; Marme F; Schneeweiss A; Cardone MH; Opferman JT; Jäger D; Podar K
    Breast Cancer Res; 2016 Feb; 18(1):26. PubMed ID: 26921175
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Oncogenic USP22 supports gastric cancer growth and metastasis by activating c-Myc/NAMPT/SIRT1-dependent FOXO1 and YAP signaling.
    Liu H; Liu N; Zhao Y; Zhu X; Wang C; Liu Q; Gao C; Zhao X; Li J
    Aging (Albany NY); 2019 Nov; 11(21):9643-9660. PubMed ID: 31689236
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Disulfide bond disrupting agents activate the unfolded protein response in EGFR- and HER2-positive breast tumor cells.
    Ferreira RB; Wang M; Law ME; Davis BJ; Bartley AN; Higgins PJ; Kilberg MS; Santostefano KE; Terada N; Heldermon CD; Castellano RK; Law BK
    Oncotarget; 2017 Apr; 8(17):28971-28989. PubMed ID: 28423644
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The SAGA complex regulates early steps in transcription via its deubiquitylase module subunit USP22.
    Stanek TJ; Gennaro VJ; Tracewell MA; Di Marcantonio D; Pauley KL; Butt S; McNair C; Wang F; Kossenkov AV; Knudsen KE; Butt T; Sykes SM; McMahon SB
    EMBO J; 2021 Aug; 40(16):e102509. PubMed ID: 34155658
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ubiquitin-specific protease 22 acts as an oncoprotein to maintain glioma malignancy through deubiquitinating B cell-specific Moloney murine leukemia virus integration site 1 for stabilization.
    Qiu GZ; Mao XY; Ma Y; Gao XC; Wang Z; Jin MZ; Sun W; Zou YX; Lin J; Fu HL; Jin WL
    Cancer Sci; 2018 Jul; 109(7):2199-2210. PubMed ID: 29788550
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Expression of USP22 and Survivin is an indicator of malignant behavior in hepatocellular carcinoma.
    Tang B; Liang X; Tang F; Zhang J; Zeng S; Jin S; Zhou L; Kudo Y; Qi G
    Int J Oncol; 2015 Dec; 47(6):2208-16. PubMed ID: 26497847
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inhibition of USP7 upregulates USP22 and activates its downstream cancer-related signaling pathways in human cancer cells.
    Zhang K; Sun T; Li W; Guo Y; Li A; Hsieh M; Wang J; Wu J; Arvanitis L; Raz DJ
    Cell Commun Signal; 2023 Nov; 21(1):319. PubMed ID: 37946202
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.